Potasyum ve kalp hastalıkları arasındaki ilişki

ŞAHİN, Mahmut; ARSLANDAĞ, Muharrem; DURSUN, İhsan

Potasyum ve kalp hastalıkları arasındaki ilişki

İhsan DURSUN, (Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Samsun, Türkiye)

Muharrem ARSLANDAĞ, (Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Samsun, Türkiye)

Mahmut ŞAHİN (Ondokuz Mayıs Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Samsun, Türkiye)

Türk Kardiyoloji Derneği Arşivi

58 2

Yıl: 2005 Cilt: 33 Sayı: 3 Sayfa Aralığı: 177 - 185 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Potasyum ve kalp hastalıkları arasındaki ilişki

Öz:

Hücre metabolizması ve membran uyarılmasında önemli rol oynayan potasyum (K+) iyonunundaki dengesizlikler, yaşamı tehdit edebilen durumlara yol açabilmesi nedeniyle önemlidir. Hem kardiyovasküler hastalıklardaki nörohormonal mekanizmalara hem de bu hastalıkların tedavisinde kullanılan ilaçlara bağlı olarak potasyum dengesi bozulabilmektedir. Malign ventriküler aritmiler ve ani ölüm, potasyum dengesizliklerinde özellikle korkulan komplikasyonlardır. Bu derlemede, potasyum dengesini etkileyen kardiyovasküler ilaçlar ve potasyum iyonu ile kalp hastalıkları arasındaki ilişki gözden geçirildi.

Anahtar Kelime: Magnezyum Potasyum Hiperkalemi Kalp damar hastalıkları Diüretikler Diyet

Konular: Kalp ve Kalp Damar Sistemi

The relationship between potassium and heart diseases

Öz:

Potassium plays an important role in cell metabolism and membrane excitability and imbalances in its concentration are important because of ensuing life-threatening conditions. Potassium balance may be disturbed by both the neurohormonal mechanisms in cardiovascular diseases and the drugs used in these diseases. In particular, complications such as malignant ventricular arrhythmias and sudden death are of great concern in potassium instability. This article reviews current knowledge on the drugs that affect potassium balance and the relationship between the potassium ion and cardiac diseases

Anahtar Kelime: Diet Magnesium Potassium Hyperkalemia Cardiovascular Diseases Diuretics

Konular: Kalp ve Kalp Damar Sistemi

Belge Türü: Makale Makale Türü: Derleme Erişim Türü: Erişime Açık

1. Gennari FJ. Hypokalemia. N Engl J Med 1998;339: 451-8.
2. Macdonald JE, Struthers AD. What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol 2004;43:155-61.
3. Halperin ML, Kamel KS. Potassium. Lancet 1998;352: 135-40.
4. Sheehan JP, Seelig MS. Interactions of magnesium and potassium in the pathogenesis of cardiovascular dis ease. Magnesium 1984;3:301-14.
5. Khan MG. Cardiac drug therapy. 6th ed. Philadelphia: W. B. Saunders; 2003.
6. He FJ, MacGregor GA. Beneficial effects of potassi um. BMJ 2001 ;323:497-501.
7. Siscovick DS, Raghunathan TE, Psaty BM, Koepsell TD, Wicklund KG, Lin X, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med 1994;330:1852-7.
8. Hollifield JW, Slaton PE. Thiazide diuretics, hypokalemia and cardiac arrhythmias. Acta Med Scand Suppl 1981; 647:67-73.
9. Bristow MR, Port JD, Kelly RA. Treatment of heart failure: pharmacological methods. In: Braunwald E, Zipes DP, Libby P, editors. Heart disease. A textbook of cardiovascular medicine. 6th ed. Philadelphia: W. B. Saunders; 2001. p. 562-99.
10. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
11. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003;289:2560-72.
12. Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004;351:585-92.
13. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
14. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure. (Evaluation of Losartan in the Elderly Study, ELITE) Lancet 1997;349:747-52.
15. McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100:1056-64.
16. Ahuja TS, Freeman D Jr, Mahnken JD, Agraharkar M, Siddiqui M, Memon A, et al. Predictors of the development of hyperkalemia in patients using angiotensin-converting enzyme inhibitors. Am J Nephrol 2000;20:268-72.
17. Brunner HR, Weaber B, Nussberger J. Angiotensin converting enzyme inhibitors. In: JVIesserli FH, editor. Cardiovascular drug therapy. 2nd ed. Philadelphia: W. B. Saunders; 1996. p. 696-7.
18. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
19. Struthers AD, MacDonald TM. Review of aldosteroneand angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004;61:663-70.
20. Gross P, Pistrosch F. Hyperkalaemia: again. Nephrol Dial Transplant 2004; 19:2163-6. 21. Schepkens H, Vanholder R, Billiouw JM, Lameire N. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am J Med 2001; 110:438 41.
22. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol 1996;78:902-7.
23. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-51.
24. Remme WJ, Swedberg K; European Society of Cardiology. Comprehensive guidelines for the diagnosis and treatment of chronic heart failure. Task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur J Heart Fail 2002;4:l 1-22.
25. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone post-acute myocardial infarction heart failure efficacy and survival study investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348: 1309-21.
26. Gheno G, Savarino C, Vellar S, Cinetto L. Heparin-induced life-threatening hyperkalemia. Ann Ital Med Int 2002;17:51-3.
27. Day JR, Chaudhry AN, Hunt I, Taylor KM. Heparin induced hyperkalemia after cardiac surgery. Ann Thorac Surg 2002;74:1698-700.
28. Koren-Michowitz M, Avni B, Michowitz Y, Moravski G, Efrati S, Golik A, et al. Early onset of hyperkalemia in patients treated with low molecular weight heparin: a prospective study. Pharmacoepidemiol Drug Saf 2004; 13:299-302.
29. Schwinger RH, Erdmann E. Heart failure and electrolyte disturbances. Methods Find Exp Clin Pharmacol 1992; 14:315-25.
30. Mason DT, Zelis R, Lee G, Hughes JL, Spann JF Jr, Amsterdam EA, et al. Current concepts and treatment of digitalis toxicity. Am J Cardiol 1971 ;27:546-59.
31. Podrid PJ. Potassium and ventricular arrhythmias. Am J Cardiol 1990;65:33E-44E.
32. Helfant RH. Hypokalemia and arrhythmias. Am J Med 1986;80:13-22.
33. Michaud GF, Sticherling C, Tada H, Oral H, Pelosi F Jr, Knight BP, et al. American Heart Association; American College of Cardiology. Relationship between serum potassium concentration and risk of recurrent ventricular tachycardia or ventricular fibrillation. J Cardiovasc Electrophysiol 2001; 12:1109-12.
34. Gregoratos G, Cheitlin MD, Conill A, Epstein AE, Fellows C, Ferguson TB Jr, et al. ACC/AHA guidelines for implantation of cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Pacemaker Implantation). J Am Coll Cardiol 1998;31:1175-209.
35. Mirvis DM, Goldberger AL. Electrocardiography. In: Braunwald E, Zipes DP, Libby P, editors. Heart disease. A textbook of cardiovascular medicine. 6th ed. Philadelphia: W. B. Saunders; 2001. p. 118-9.
36. Bashour TT. Spectrum of ventricular pacemaker exit block owing to hyperkalemia. Am J Cardiol 1986;57: 337-8.
37. Wang K. Images in clinical medicine. "Pseudoinfarction" pattern due to hyperkalemia. N Engl J Med 2004;351:593.
38. Young DB, Ma G. Vascular protective effects of potassium. Semin Nephrol 1999; 19:477-86.
39. Landmark K. Hypokalemia can accelerate the development of cerebrovascular and cardiovascular disease. Tidsskr Nor Laegeforen 2002; 122:499-501. [Abstract]
40. Madias JE, Shah B, Chintalapally G, Chalavarya G, Madias NE. Admission serum potassium in patients with acute myocardial infarction: its correlates and value as a determinant of in-hospital outcome. Chest 2000;118:904-13.
41. Nordrehaug JE. Malignant arrhythmia in relation to serum potassium in acute myocardial infarction. Am J Cardiol 1985;56:20-23.
42. Cooper WD, Kuan P, Reuben SR, VandenBurg MJ. Cardiac arrhythmias following acute myocardial infarction: associations with the serum potassium level and prior diuretic therapy. Eur Heart J 1984;5: 464-9.
43. Solomon RJ, Cole AG. Importance of potassium in patients with acute myocardial infarction. Acta Med Scand Suppl 1981 ;647:87-93.
44. Gettes LS. Electrolyte abnormalities underlying lethal and ventricular arrhythmias. Circulation 1992;85(1 Suppl):170-6.
45. Opie LH, Nathan D, Lubbe WF. Biochemical aspects of arrhythmogenesis and ventricular fibrillation. Am J Cardiol 1979;43:131-48.
46. Foo K, Sekhri N, Deaner A, Knight C, Suliman A, Ranjadayalan K, et al. Effect of diabetes on serum potassium concentrations in acute coronary syndromes. Heart 2003;89:31-5.
47. Beck O A, Hochrein H. Initial serum potassium level in relation to cardiac arrhythmias in acute myocardial infarction. Z Kardiol 1977;66:187-90. [Abstract]
48. Nordrehaug JE, Johannessen KA, von der Lippe G. Serum potassium concentration as a risk factor of ven¬tricular arrhythmias early in acute myocardial infarction. Circulation 1985;71:645-9.
49. Cohn JN, Kowey PR, Whelton PK, Prisant LM. New guidelines for potassium replacement in clinical practice : a contemporary review by the National Council on Potassium in Clinical Practice. Arch Intern Med 2000; 160:2429-36.
50. Jarman PR, Mather HM. Diabetes may be independent risk factor for hyperkalaemia. BMJ 2003;327:812.

APA	DURSUN İ, ARSLANDAĞ M, ŞAHİN M (2005). Potasyum ve kalp hastalıkları arasındaki ilişki. , 177 - 185.
Chicago	DURSUN İhsan,ARSLANDAĞ Muharrem,ŞAHİN Mahmut Potasyum ve kalp hastalıkları arasındaki ilişki. (2005): 177 - 185.
MLA	DURSUN İhsan,ARSLANDAĞ Muharrem,ŞAHİN Mahmut Potasyum ve kalp hastalıkları arasındaki ilişki. , 2005, ss.177 - 185.
AMA	DURSUN İ,ARSLANDAĞ M,ŞAHİN M Potasyum ve kalp hastalıkları arasındaki ilişki. . 2005; 177 - 185.
Vancouver	DURSUN İ,ARSLANDAĞ M,ŞAHİN M Potasyum ve kalp hastalıkları arasındaki ilişki. . 2005; 177 - 185.
IEEE	DURSUN İ,ARSLANDAĞ M,ŞAHİN M "Potasyum ve kalp hastalıkları arasındaki ilişki." , ss.177 - 185, 2005.
ISNAD	DURSUN, İhsan vd. "Potasyum ve kalp hastalıkları arasındaki ilişki". (2005), 177-185.

APA	DURSUN İ, ARSLANDAĞ M, ŞAHİN M (2005). Potasyum ve kalp hastalıkları arasındaki ilişki. Türk Kardiyoloji Derneği Arşivi, 33(3), 177 - 185.
Chicago	DURSUN İhsan,ARSLANDAĞ Muharrem,ŞAHİN Mahmut Potasyum ve kalp hastalıkları arasındaki ilişki. Türk Kardiyoloji Derneği Arşivi 33, no.3 (2005): 177 - 185.
MLA	DURSUN İhsan,ARSLANDAĞ Muharrem,ŞAHİN Mahmut Potasyum ve kalp hastalıkları arasındaki ilişki. Türk Kardiyoloji Derneği Arşivi, vol.33, no.3, 2005, ss.177 - 185.
AMA	DURSUN İ,ARSLANDAĞ M,ŞAHİN M Potasyum ve kalp hastalıkları arasındaki ilişki. Türk Kardiyoloji Derneği Arşivi. 2005; 33(3): 177 - 185.
Vancouver	DURSUN İ,ARSLANDAĞ M,ŞAHİN M Potasyum ve kalp hastalıkları arasındaki ilişki. Türk Kardiyoloji Derneği Arşivi. 2005; 33(3): 177 - 185.
IEEE	DURSUN İ,ARSLANDAĞ M,ŞAHİN M "Potasyum ve kalp hastalıkları arasındaki ilişki." Türk Kardiyoloji Derneği Arşivi, 33, ss.177 - 185, 2005.
ISNAD	DURSUN, İhsan vd. "Potasyum ve kalp hastalıkları arasındaki ilişki". Türk Kardiyoloji Derneği Arşivi 33/3 (2005), 177-185.